NASDAQ:TRML Tourmaline Bio (TRML) Stock Price, News & Analysis $16.89 -0.43 (-2.48%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$17.26 +0.37 (+2.19%) As of 04/25/2025 05:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Tourmaline Bio Stock (NASDAQ:TRML) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Tourmaline Bio alerts:Sign Up Key Stats Today's Range$16.54▼$17.6150-Day Range$12.10▼$18.8052-Week Range$11.56▼$29.79Volume217,668 shsAverage Volume268,572 shsMarket Capitalization$433.82 millionP/E RatioN/ADividend YieldN/APrice Target$49.33Consensus RatingBuy Company OverviewTourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.Read More… Tourmaline Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreTRML MarketRank™: Tourmaline Bio scored higher than 48% of companies evaluated by MarketBeat, and ranked 708th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingTourmaline Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTourmaline Bio has only been the subject of 4 research reports in the past 90 days.Read more about Tourmaline Bio's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Tourmaline Bio are expected to decrease in the coming year, from ($3.02) to ($3.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tourmaline Bio is -5.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tourmaline Bio is -5.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTourmaline Bio has a P/B Ratio of 1.68. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Tourmaline Bio's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted19.08% of the float of Tourmaline Bio has been sold short.Short Interest Ratio / Days to CoverTourmaline Bio has a short interest ratio ("days to cover") of 8.8.Change versus previous monthShort interest in Tourmaline Bio has recently decreased by 5.26%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTourmaline Bio does not currently pay a dividend.Dividend GrowthTourmaline Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted19.08% of the float of Tourmaline Bio has been sold short.Short Interest Ratio / Days to CoverTourmaline Bio has a short interest ratio ("days to cover") of 8.8.Change versus previous monthShort interest in Tourmaline Bio has recently decreased by 5.26%, indicating that investor sentiment is improving significantly. News and Social Media2.5 / 5News Sentiment0.57 News SentimentTourmaline Bio has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.03 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Tourmaline Bio this week, compared to 2 articles on an average week.Search Interest1 people have searched for TRML on MarketBeat in the last 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Tourmaline Bio insiders have not sold or bought any company stock.Percentage Held by Insiders11.02% of the stock of Tourmaline Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions91.89% of the stock of Tourmaline Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tourmaline Bio's insider trading history. Receive TRML Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tourmaline Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address TRML Stock News HeadlinesTourmaline Bio (NASDAQ:TRML) Earns Buy Rating from Analysts at Chardan CapitalApril 26 at 2:26 AM | americanbankingnews.comKrystal Biotech (NASDAQ:KRYS) and Tourmaline Bio (NASDAQ:TRML) Head-To-Head ComparisonApril 24 at 1:11 AM | americanbankingnews.comTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 27, 2025 | Porter & Company (Ad)Tourmaline Bio initiated with a Buy at ChardanApril 23, 2025 | markets.businessinsider.comTourmaline Bio (TRML) Gets a Buy from Chardan CapitalApril 23, 2025 | markets.businessinsider.comChardan Capital Initiates Coverage of Tourmaline Bio (TRML) with Buy RecommendationApril 23, 2025 | msn.comHere's Why We're Not Too Worried About Tourmaline Bio's (NASDAQ:TRML) Cash Burn SituationApril 19, 2025 | finance.yahoo.comTourmaline Bio price target lowered to $63 from $74 at TruistApril 11, 2025 | markets.businessinsider.comSee More Headlines TRML Stock Analysis - Frequently Asked Questions How have TRML shares performed this year? Tourmaline Bio's stock was trading at $20.28 at the start of the year. Since then, TRML stock has decreased by 16.7% and is now trading at $16.89. View the best growth stocks for 2025 here. How were Tourmaline Bio's earnings last quarter? Tourmaline Bio, Inc. (NASDAQ:TRML) issued its quarterly earnings results on Thursday, March, 13th. The company reported ($0.86) earnings per share for the quarter, topping the consensus estimate of ($0.91) by $0.05. The company had revenue of $0.04 million for the quarter. Who are Tourmaline Bio's major shareholders? Tourmaline Bio's top institutional shareholders include SG Americas Securities LLC (0.14%), Rhumbline Advisers (0.13%) and GAMMA Investing LLC (0.03%). Insiders that own company stock include Mark Mcdade, Parvinder Thiara and Sandeep Chidambar Kulkarni. View institutional ownership trends. How do I buy shares of Tourmaline Bio? Shares of TRML stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tourmaline Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tourmaline Bio investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and Southern First Bancshares (SFST). Company Calendar Last Earnings3/13/2025Today4/26/2025Next Earnings (Estimated)5/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TRML Previous SymbolNASDAQ:TRML CIK1827506 WebN/A Phone502-398-9250FaxN/AEmployees44Year FoundedN/APrice Target and Rating Average Stock Price Target$49.33 High Stock Price Target$70.00 Low Stock Price Target$25.00 Potential Upside/Downside+192.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-42,120,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-20.97% Return on Assets-20.56% Debt Debt-to-Equity RatioN/A Current Ratio40.33 Quick Ratio40.33 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$10.08 per share Price / Book1.68Miscellaneous Outstanding Shares25,685,000Free Float22,817,000Market Cap$433.82 million OptionableOptionable Beta2.14 The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:TRML) was last updated on 4/27/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tourmaline Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tourmaline Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.